In this in vitro study, pERK was confirmed to be a potential biomarker predictive of sensitivity to sorafenib in treating HCC. The RAF/MEK/ERK pathway may be involved in drug resistance to traditional chemotherapy in HCC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: